Holen Sie sich die Stockscreener-App
0.6947
2.46%
0.0167
Handel nachbörslich:
.69
-0.0047
-0.68%
Schlusskurs vom Vortag:
$0.678
Offen:
$0.6461
24-Stunden-Volumen:
22,142
Relative Volume:
0.20
Marktkapitalisierung:
$2.03M
Einnahmen:
$4.51M
Nettoeinkommen (Verlust:
$-7.66M
KGV:
-0.1839
EPS:
-3.778
Netto-Cashflow:
$-7.51M
1W Leistung:
+12.96%
1M Leistung:
-24.49%
6M Leistung:
-68.99%
1J Leistung:
-62.65%
1-Tages-Spanne:
$0.6461
$0.6947
1-Wochen-Bereich:
$0.575
$0.6947
52-Wochen-Spanne:
$0.575
$7.98
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Firmenname
Inmed Pharmaceuticals Inc
Sektor
Telefon
(604) 669-7207
Adresse
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
0.6947 | 1.98M | 4.51M | -7.66M | -7.51M | -3.778 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Inmed Pharmaceuticals Inc Aktie (INM) Neueste Nachrichten
Price performance - Yahoo Finance Singapore
Published on: 2026-04-05 13:17:10 - baoquankhu1.vn
InMed Pharmaceuticals Inc. Files Form 8-K Current Report with SEC – Company Information, Nasdaq Listing, and Legal Opinion Included - Minichart
InMed Pharmaceuticals files prospectus supplement for at-the-market share offering - Investing.com
InMed Pharmaceuticals Announces ATM Offering Prospectus Filing - tipranks.com
InMed Pharmaceuticals files prospectus supplement for ATM share sales under amended sales agreement - TradingView
InMed (NASDAQ: INM) files ATM prospectus supplement under S-3 shelf - Stock Titan
InMed Pharmaceuticals (NASDAQ: INM) files $1.21M ATM offering with 3.0% fee - Stock Titan
[EFFECT] InMed Pharmaceuticals Inc. SEC Filing - Stock Titan
InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance - tipranks.com
InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] InMed Pharmaceuticals Inc. Reports Material Event - Stock Titan
InMed receives Nasdaq minimum bid price deficiency notice By Investing.com - Investing.com Australia
InMed warned by Nasdaq over minimum bid price non-compliance - TipRanks
InMed Pharmaceuticals Notified of Nasdaq Non-Compliance with $1 Minimum Bid Price Rule - geneonline.com
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Investing News Network
InMed receives Nasdaq minimum bid price deficiency notice - Investing.com
InMed Pharma gets Nasdaq non-compliance notice - MSN
InMed Pharmaceuticals Inc.Common Shares (NQ: INM - The Chronicle-Journal
InMed Pharmaceuticals Reports Positive INM-901 Data in Human Brain Organoid Models for Alzheimer’s Disease Program 12 - Minichart
InMed reports preclinical data on Alzheimer’s drug candidate By Investing.com - Investing.com Australia
InMed Pharmaceuticals Inc. (INM) Stock: Shows Promising Anti-Inflammatory Effects in 3D Brain Organoid Study - parameter.io
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with N - GuruFocus
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program - Investing News Network
InMed Reports Positive Preclinical Data for Alzheimer’s Candidate - TipRanks
InMed reports preclinical data on Alzheimer’s drug candidate - Investing.com
InMed Pharmaceuticals Inc recently released positive research data for its Alzheimer's disease treatment project INM-901, according to documents submitted to the U.S. Securities and Exchange Commission (SEC). - Bitget
InMed (NASDAQ: INM) reports INM-901 organoid data, targets Phase 1 in 2027 - Stock Titan
Aug Decliners: Can InMed Pharmaceuticals Inc outperform under higher oil pricesWeekly Market Outlook & Low Drawdown Trading Strategies - baoquankhu1.vn
[S-3] InMed Pharmaceuticals Inc. Shelf Registration Statement - Stock Titan
Aug Weekly: Can InMed Pharmaceuticals Inc be the next market leaderBear Alert & Accurate Entry/Exit Alerts - baoquankhu1.vn
Ideas Watch: Can InMed Pharmaceuticals Inc be the next market leader2026 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Published on: 2026-03-17 19:00:00 - baoquankhu1.vn
CEO Moves: Will InMed Pharmaceuticals Inc stock go up in YEAR2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
InMed Pharmaceuticals Advances INM-901 for Alzheimer’s and INM-089 for Macular Degeneration with FDA Engagement Planned for 2026-2027 1 - Minichart
InMed Pharmaceuticals (INM) Sets 2026 Development Goals - gurufocus.com
InMed Provides Update on Pharmaceutical Development ProgramsAdvancing Lead Drug Candidates Towards IND and Clinical Trial - Investing News Network
InMed outlines 2026 development plans for lead programs - TipRanks
InMed Provides 2026 Development Outlook; Targets FDA pre-IND for INM-901 and Phase 1 in 2027 - TradingView
InMed (INM) sets 2026 goals for Alzheimer’s and eye-disease drug programs - Stock Titan
InMed's 2026 push to bring Alzheimer's, eye drug candidates to human testing - Stock Titan
Can InMed Pharmaceuticals Inc reach all time highs this yearJuly 2025 Technicals & Weekly Momentum Picks - baoquankhu1.vn
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline - Investing News Network
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), InMed Pharmaceuticals Inc (INM) officially confirmed and passed a resolution on March 4 to gradually terminate the commercial operations of its Baymedica divisio - Bitget
InMed Pharmaceuticals Exits BayMedica to Refocus on Pipeline - TipRanks
InMed Pharmaceuticals IncOn March 4, Co Confirmed And Approved The Decision To Wind Down Baymedica's Commercial OperationsSEC Filing - TradingView
InMed (NASDAQ: INM) winds down BayMedica unit and pivots fully to drug development - Stock Titan
INM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can InMed Pharmaceuticals Inc. reach all time highs this yearQuarterly Performance Summary & Technical Confirmation Trade Alerts - mfd.ru
Risk Off: Can InMed Pharmaceuticals Inc be the next market leaderMarket Trend Report & Daily Volume Surge Signals - baoquankhu1.vn
Finanzdaten der Inmed Pharmaceuticals Inc-Aktie (INM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):